ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680
ALKS 2680-301
Phase 3 small_molecule active
Quick answer
ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680 for Narcolepsy Type 1, Type 2 and Idiopathic Hypersomnia is a Phase 3 program (small_molecule) at Alkermes Pharma Ireland with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Alkermes Pharma Ireland
- Indication
- Narcolepsy Type 1, Type 2 and Idiopathic Hypersomnia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active